WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012121958) COMBINATION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/121958    International Application No.:    PCT/US2012/027177
Publication Date: 13.09.2012 International Filing Date: 01.03.2012
IPC:
A61P 7/04 (2006.01)
Applicants: GLAXOSMITHKLINE LLC [US/US]; One Franklin Plaza 200 North 16th Street Philadelphia, PA 19102 (US) (For All Designated States Except US).
BRAINSKY, Andres [CO/US]; (US) (For US Only)
Inventors: BRAINSKY, Andres; (US)
Agent: DUSTMAN, Wayne J.; Glaxosmithkline Corporate Intellectual Property, Uw2220 709 Swedeland Road, P.o. Box 1539 King Of Prussia, PA 19406-0939 (US)
Priority Data:
61/450,289 08.03.2011 US
Title (EN) COMBINATION
(FR) ASSOCIATION
Abstract: front page image
(EN)The present invention relates generally to the use of eltrombopag in combination with an anti-CD20 antibody to treat thrombocytopenia, suitably immune thrombocytopenia purpura. In one embodiment, the present invention relates a method of treating, thrombocytopenia, suitably immune thrombocytopenia purpura, suitably rituximab refractory immune thrombocytopenia purpura, in a human patient, comprising the step of administering to the patient an anti-CD20 antibody in combination with eltrombopag, suitably eltrombopag olamine. In one embodiment, the administration is simultaneous. In another embodiment, the administration is sequential in which eltrombopag, suitably eltrombopag olamine is administered first. Yet in another embodiment, an anti-CD20 antibody is administered first. In yet in another embodiment, administration of an antiCD20 antibody and eltrombopag, suitably eltrombopag olamine is staggered.
(FR)De manière générale, cette invention concerne l'utilisation d'eltrombopag en association avec un anticorps anti-CD20 pour traiter la thrombopénie, et de manière avantageuse, le purpura thrombopénique idiopathique.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)